MacroGenics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MacroGenics and other ETFs, options, and stocks.

About MGNX

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases.

CEO

Scott E. Koenig

CEOScott E. Koenig

Employees

341

Employees341

Headquarters

Rockville, Maryland

HeadquartersRockville, Maryland

Founded

2000

Founded2000

Employees

341

Employees341

MGNX Key Statistics

Market cap

100.00M

Market cap100.00M

Price-Earnings ratio

-1.78

Price-Earnings ratio-1.78

Dividend yield

—

Dividend yield—

Average volume

396.88K

Average volume396.88K

High today

$1.62

High today$1.62

Low today

$1.51

Low today$1.51

Open price

$1.54

Open price$1.54

Volume

401.48K

Volume401.48K

52 Week high

$5.77

52 Week high$5.77

52 Week low

$0.9897

52 Week low$0.9897

MGNX News

Simply Wall St 4d

MacroGenics First Quarter 2025 Earnings: Beats Expectations

MacroGenics ( ) First Quarter 2025 Results Key Financial Results Revenue: US$13.2m (up 45% from 1Q 2024). Net loss: US$41.0m (loss narrowed by 21% from 1Q 20...

TipRanks 5d

MacroGenics price target lowered to $3 from $8 at Barclays

Barclays analyst Peter Lawson lowered the firm’s price target on MacroGenics (MGNX) to $3 from $8 and keeps an Overweight rating on the shares post the earnings...

Analyst ratings

71%

of 7 ratings

Buy

28.6%

Hold

71.4%

Sell

People also own

Based on the portfolios of people who own MGNX. This list is generated using Robinhood data, and it’s not a recommendation.